| Ytd | -25.42% | |
| 1y | 28.23% |
| Open | 4.00 | Prev Close | 4.11 | Low | 3.85 | High | 4.03 | Mkt Cap | 223.41M |
| Vol | 394.84K | Avg Vol | 665.72K | EPS | -1.34 | P/E | -2.97 | Forward P/E | -1.61 |
| Beta | 1.50 | Short Ratio | 14.46 | Inst. Own | 51.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.07 | 200-d Avg | 5.24 | 1yr Est | 26.40 |
TARA News
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the a
Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the cur
Shares of Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) have received an average ratin
Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, whic
MIAMI, July 20, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) today announced the appointme
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading
$100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD C
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperfor
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-sta
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002
Protara Therapeutics Inc. (NASDAQ:TARA) reported updated 12-month Phase 2 data for TARA-002 in patie
Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-mo
JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the ana
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malfor
HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics (NASDAQ:TARA) with
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transfor
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-s
Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) was the recipient of a large increase in
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.37) per share which missed the a
Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002
JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Ove
Protara Therapeutics (NASDAQ: TARA) executives outlined progress across the company's two clinical-s
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Inva
Protara Therapeutics (TARA) shares down after release of interim results for TARA-002 treatment of N
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse event
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse event
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-st
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA)
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapi
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-st
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patien
Piper Sandler analyst Kelsey Goodwin initiates coverage on Protara Therapeutics (NASDAQ:TARA) wit
Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapi
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therap
Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara"), a clinical-stage company developing tr
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA)
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therap